Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with atherosclerotic cardiovascular disease; however, many pati...

Full description

Bibliographic Details
Main Authors:	Chandni Bardolia, Nishita Shah Amin, Jacques Turgeon
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-11-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	ezetimibe PCSK9 inhibitors alirocumab evolocumab bempedoic acid inclisiran
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2021.789931/full

Similar Items

Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol
by: Peter P. Toth, et al.
Published: (2022-09-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
by: Nicola Ferri, et al.
Published: (2024-02-01)

The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023-09-01)

Safety of PCSK9 inhibitors
by: Grzegorz Grześk, et al.
Published: (2022-12-01)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
by: Fairman KA, et al.
Published: (2017-08-01)

Assessment of the global and national market for lipid modifying agents: retrospective and innovation
by: A. V. Lokhmacheva, et al.
Published: (2023-08-01)

Traditional and novel non-statin lipid-lowering drugs
by: Peeyush Jain
Published: (2024-03-01)

Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
by: Edyta Kinga Prokop, et al.
Published: (2019-04-01)

The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus
by: Aleksandra Frątczak, et al.
Published: (2022-09-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Current Options and Future Perspectives in the Treatment of Dyslipidemia
by: Saverio Muscoli, et al.
Published: (2022-08-01)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
by: Zhen Feng, et al.
Published: (2022-11-01)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
by: Joshua Choi, et al.
Published: (2017-07-01)

Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
by: Gianni Biolo, et al.
Published: (2022-10-01)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
by: Rahayu Zulkapli, et al.
Published: (2023-03-01)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat
by: Hong-Fei Wang, et al.
Published: (2022-12-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
by: Achim Leo Burger, et al.
Published: (2022-04-01)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
by: Adrianna Dec, et al.
Published: (2023-04-01)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023-12-01)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
by: Marina Blanco-Ruiz, et al.
Published: (2021-11-01)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
by: Farzahna Mohamed, et al.
Published: (2023-08-01)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
by: Henry CA, et al.
Published: (2016-04-01)

PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration
by: Jessica Eloso, et al.
Published: (2023-06-01)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
by: Peter P. Toth, et al.
Published: (2017-10-01)

New and emerging lipid-modifying drugs to lower LDL cholesterol
by: Constantine E Kosmas, et al.
Published: (2021-10-01)

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)
by: Jose A. Caparrós-Martín, et al.
Published: (2024-01-01)

Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023
by: N Katsiki, et al.
Published: (2024-03-01)

PCSK9: NEW VICTORY AND HORIZONS
by: M. O. Smolina, et al.
Published: (2018-09-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017-05-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
by: Mario Luca Morieri, et al.
Published: (2021-07-01)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
by: Helen M. Colhoun, et al.
Published: (2020-02-01)

Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update
by: Fabiana Lucà, et al.
Published: (2023-08-01)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients
by: Gianluigi Cuomo, et al.
Published: (2022-06-01)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
by: Federica Fogacci, et al.
Published: (2021-08-01)

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels
by: Maria K. Svensson, et al.
Published: (2024-01-01)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023-01-01)